Polymeric nanoparticle encapsulating Docetaxel for prolonged and targeted delivery to breast cancer
DOI:
https://doi.org/10.56511/JIPBS.2017.v4.i04.pp132-140Abstract
Chitosan nanoparticles (HA-CHI-NP) containing docetaxel (DTX) were prepared, by ionotropic gelation method and further coupled with hyaluronic acid for targeting effect, in the treatment of breast cancer. Nanoparticles (NP’s) have been characterized for the particle size, stability and shape with the help of zeta sizer, zeta potential and SEM. NP’s were found to be spherical in shape and the size were around 97.36 ± 3.07 nm with 0.5 polydispersity index. NP’s were also characterized for FTIR, DSC and PXRD. The in-vitro drug release of plain DTX and docetaxel loaded chitosan nanoparticle (DTX-CHI-NP) revealed higher and prolonged release of drug from DTX-CHI-NP than with plain DTX. In-vitro cytotoxicity was assessed by MTT assay using MCF-7 cell lines at different concentration (5, 10, 25, 50 and 100 µg/ml) and time intervals (24, 48 and 72h). Higher inhibitory effect of DTX-CHI-NP was observed with an IC50 value of approximately 2.18 µg/ml at 72h. The formulation was also assessed for pharmacokinetic profile, biodistribution and tumour inhibition effect
Keywords:
Hyaluronic acid, Chitosan, Docetaxel, Breast cancer, Cytotoxicity, Tumour inhibitionDownloads
References
Suarato G, Li W, and Meng Y: Role of pH-responsiveness in the design of chitosan-based cancernanotherapeutics: A review. Bio interphases. 2016; doi:10.1116/1.4944661.
Arola OJ , Saraste A , Pulkki K , Kallajoki M , Parvinen M , Voipio-Pulkki LM : Acute doxorubicin cardiotoxicity involves cardiomyocyteapoptosis. Cancer Res 2000; 60: 1789-1792.
Liu B , Yang M , Li R , Ding Y , Qian X , Yu L , Jiang X : The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm 2008; 69: 527-534.
Tammam SN, Azzazy HM , Lamprecht A . Biodegradable particulate carrier formulation and tuning for targeted drug delivery. J Biomed Nanotechnol 2015; 11: 555-577.
Gao H , Cao S , Yang Z , Zhang S , Zhang Q , Jiang X : Preparation, characterization and anti-glioma effects of docetaxel-incorporated albumin-lipid nanoparticles. J Biomed Nanotechnol 2015; 11: 2137-2147.
Nukolova NV , Oberoi HS , Cohen SM , Kabanov AV , Bronich TK : Folatedecorated nanogels for targeted therapy of ovarian cancer. Biomaterials 2011; 32:5417-5426.
Talelli M , Iman M , Varkouhi AK , Rijcken CJ , Schiffelers RM , Etrych T , Ulbrich K , van Nostrum CF , Lammers T , Storm G , Hennink WE : Corecrosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 2010; 31: 7797-7804.
Huang W-T, Larsson M, Wang Y-J, Chiou S-H,Lin H-Y, and Liu D-M: Demethoxy curcuminCarrying Chitosan−Antibody Core−Shell Nanoparticles with Multi therapeutic Efficacy toward Malignant A549Lung Tumor: From in Vitro Characterization to in Vivo Evaluation. Mol. Pharmaceutics. Doi: 10.1021/mp500747w.
Jiang Y, Yang N, Zhang H, Sun B, Hou C, Ji C, Zheng J, Liu Y, Zuo P: Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. Journal of Controlled Release 2016; 221: 26 – 36.
Akima K, Ito H, Iwata Y, Matsuo K, Watari N, Yanagi M, Hagi H, Oshima K, Yagita A, Atomi Y, Tatekawa I: Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J. Drug Target 1996; 4: 1 – 8.
Luo Y, Prestwich GD: Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem. 1999; 10: 755 – 763.
Peterson RM, Yu Q, Stamenkovic I, Toole BP: Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol. 2000; 156: 2159 – 2167.
Jain A & Jain SK: In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumour. European journal of pharmaceutical sciences 2008; 35: 404-416.
Weiss RB, Donehower RC, Wiernik PH: Hypersensitivity reactions fromtaxol. J. Clin. Oncol. 1990; 8: 1263-1268.
Kraynak MA: Pharmaceutical aspects of docetaxel. Am. J. Health Syst. Pharm.1997; S7-S10.
Immordino ML, Brusa P, Arpicco S: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control Release 2003; 91: 417-429.
Alexopoulos A, Karamouzis MV, Stavrinides H: Phase II study of pegylated liposomal doxorubicin (caelyx) and docetaxel as first-line treatment inmetastatic breast cancer. Ann. Oncol. 2004; 15: 891-895.
Grosse PY, Bressolle F, Pinguet F: In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl- β -cyclodextrin. Eur. J. Cancer 1998; 34:168-174.
He Y, Li P, Yalkowsky SH: Solubilization of fluasterone in cosolvent/cyclodextrin combinations. Int. J. Pharm. 2003; 264: 25-34.
Yalkowsky SH, Roseman TJ: Solubilization of drugs by co-solvents. In:Yalkowsky, S.H. (Ed.), Techniques of Solubilization of Drug. Marcel Dekker Inc,New York, NY.1981; 91-134.
Kawakami K, Miyoshi K, Ida Y: Solubilization behavior of poorly soluble drugs with combined use of Gelucire 44/14 and cosolvent. J. Pharm. Sci. 2004; 93:1471-1479.
Parka M-O, Keuma C-G, Song J-Y, Kim D, Cho C-W: A novel aqueous parenteral formulation of docetaxel using pro drugs. International Journal of Pharmaceutics 2014; 462:1-7.
Kiilll CP, Barud H dS, Santagneli SH, Ribeiro SJL, Silva AM, Tercjak A, Gutierrez J, Pironi AM, Gremião MPD: Synthesis and factorial design applied to a novel chitosan/sodium polyphosphate nanoparticles via ionotropic gelation as an RGD delivery system. Carbohydrate Polymers 2016;doi:10.1016/j.carbpol.2016.11.053.
Calvo P, Remu˜nán -López C, Vila-Jato JL & Alonso MJ: Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. Journal of Applied Polymer Science 1997; 63(1): 125 – 132.
Momin MM, Zaheer Z, Zainuddin R & Sangshetti J.N: Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer. Artificial Cells, Nanomedicine, and Biotechnology 2017; doi: 10.1080/21691401.2017.1360324.
Zainuddin R, Zaheer Z, Sangshetti JN & Momin MM. Enhancement of oral bioavailability of anti-HIV drug Rilpivirine HCl through nanosponge formulation. Drug Development and Industrial Pharmacy 2017; doi: 10.1080/03639045.2017.1371732.
Tang X, Wang G, Shi R, Jiang K, Meng L, Ren H, Wu J and Hu Y: Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles 2015; doi: 10.3109/10717544.2015.1049720.
Gupta Y, Jain A, Jain P, Jain SK: Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J. Drug Target 2007; 15(3): 231 – 240.
PeršeM, CerarA, InjacR &Štrukelj B: N-methylnitrosourea Induced Breast Cancerin Rat, the Histopathology of the Resulting Tumours and its Drawbacks as a Model. Pathol. Oncol. Res. 2009; 15:115 – 121.
Hu Q, Rijcken CJ, Bansal R, Hennink WE, Storm G, Prakash J: Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials 2015; 53:370e378.
Lembo D, Swaminathan S, Donalisio M, Civra A, Pastero L,Aquilano D, Vavia P, Trotta F, Cavalli R: Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent’s antiviral efficacy. International Journal of Pharmaceutics 2013; 443: 262 – 272.
Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA – PEG block copolymer. J. Controlled Release 2001; 70: 63 – 70.
Published
How to Cite
Issue
Section
Copyright (c) 2017 Mufassir Momin, Zahid Zaheer, Rana Zainuddin, Jaiprakash N. Sangshetti
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at